Program Overview

The Bridge Program is convened and administered by QUT and involves a consortium of 10 pharmaceutical companies, universities and industry associations. The Bridge Program aims to boost the commercial outputs of Australian pharmaceutical research by improving the quality and quantity of commercial deals that arise from Australia’s pharmaceutical research sector.

Launched in 2017, the program selects 100 participants annually from across Australia to take part in face-to-face and online training in the scientific, legal, financial, clinical, regulatory and reimbursement disciplines that contribute to research translation and the commercialisation of medicines. Program participants also benefit from direct exposure to networking opportunities with top pharmaceutical companies operating globally.

As part of the MTPConnect Project Fund Program, the Bridge Program was awarded industry matched funding to deliver an exciting education program that provides the necessary training to enable successful commercialisation of Australian pharmaceutical research.  The Bridge Program is unique in its integration into venture capital and global pharmaceutical networks and its ability to share specific, detailed and practical know-how that will assist researchers and entrepreneurs to improve the quality and quantity of leads that they could offer for development, and to accelerate the process of commercialisation.


2020 Partnership Opportunity

In 2020 the Bridge Program will receive funding through MTPConnect’s Biomedical Translation Bridge Fund along with industry matched funding from partner companies. The Bridge Consortium therefore has an opportunity to include new members to support and take part in the design and delivery of this unique program. Please contact us using the form below to express your interest in this opportunity.